TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30744517

Group type: EXPERIMENTAL
Intervention: Transcranial Pulsed Electromagnetic Fields (active treatment)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Placebo treatment (control)
Number of subjects: 97
Study: 27213785

Group type: EXPERIMENTAL
Intervention: Early laparoscopic cholecystectomy (LC) within three days after ERCP
Number of subjects: 56

Group type: COMPARATOR
Intervention: Late laparoscopic cholecystectomy (LC) one month after ERCP
Number of subjects: 56
Study: 24739486

Group type: EXPERIMENTAL
Intervention: Deproteinization Technique (10% NaOCl for 1 min + Prime & Bond NT)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Conventional Technique (acid etching with 37% phosphoric acid + Prime & Bond NT)
Number of subjects: 30
Study: 22447003

Group type: EXPERIMENTAL
Intervention: Automatic 80 beats/min IABP‐induced pulsatile CPB (Group B)
Number of subjects: 501

Group type: COMPARATOR
Intervention: Linear cardiopulmonary bypass (Group A)
Number of subjects: 501
Study: 20523050

Group type: EXPERIMENTAL
Intervention: Rivastigmine 3-12 mg/day (capsules bid)
Number of subjects: 541

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 541
Study: 18477074

Group type: EXPERIMENTAL
Intervention: Levosimendan
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 16006298

Group type: EXPERIMENTAL
Intervention: Substitution of 12.5 microg of liothyronine (LT(3)) for 50 microg of levothyroxine (LT(4))
Number of subjects: 30

Group type: COMPARATOR
Intervention: Levothyroxine (LT(4)) alone
Number of subjects: 30
Study: 12865611

Group type: EXPERIMENTAL
Intervention: Induced blood pressure elevation (treated patients, n = 9)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Conventional management (untreated patients, n = 6)
Number of subjects: 15
Study: 11063155

Group type: EXPERIMENTAL
Intervention: Low SPGI levels (< 25 microg/l) with diagnostic gastroscopy
Number of subjects: 1344

Group type: COMPARATOR
Intervention: Control group with SPGI >= 50 microg/l
Number of subjects: 1344

Group type: EXPERIMENTAL
Intervention: Low SPGI levels with severe neoplastic lesions
Number of subjects: 1344

Group type: EXPERIMENTAL
Intervention: Curative treatment for early cancer or high-grade dysplasia
Number of subjects: 1344

Group type: EXPERIMENTAL
Intervention: 5-year survival rate among gastric cancer cases
Number of subjects: 1344
Study: 9279143

Group type: EXPERIMENTAL
Intervention: Extensively hydrolysed formula (N)
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: Partially hydrolysed formula (PH)
Number of subjects: 155

Group type: COMPARATOR
Intervention: Regular formula (RM)
Number of subjects: 155
Study: 8290862

Group type: EXPERIMENTAL
Intervention: Face mask breathing through the mouth only (FM/mouth)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Face mask breathing through the nose only (FM/nose)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mouthpiece with nose-clip (MP+NC)
Number of subjects: 0
Study: 2423800

Group type: EXPERIMENTAL
Intervention: Indoramin (50-100 mg/day)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Pindolol (10-20 mg/day)
Number of subjects: 60
Study: 29667449

Group type: EXPERIMENTAL
Intervention: Ibuprofen lysine
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Ibuprofen liquid capsule
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Ibuprofen sodium
Number of subjects: 32

Group type: COMPARATOR
Intervention: Ibuprofen acid (reference)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Ibuprofen salts (overall)
Number of subjects: 32
Study: 26865445

Group type: EXPERIMENTAL
Intervention: Bivalirudin
Number of subjects: 11623

Group type: COMPARATOR
Intervention: Abciximab plus UFH
Number of subjects: 11623

Group type: COMPARATOR
Intervention: UFH alone
Number of subjects: 11623
Study: 24420549

Group type: EXPERIMENTAL
Intervention: Intranasal angiotensin II (400 μg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 24085050

Group type: EXPERIMENTAL
Intervention: Pimecrolimus cream 1%
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tacrolimus ointment 0.03%
Number of subjects: 0
Study: 20872550

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 0

Group type: COMPARATOR
Intervention: No concomitant treatment (Control)
Number of subjects: 0
Study: 18194506

Group type: EXPERIMENTAL
Intervention: Fospropofol 2 mg/kg
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Fospropofol 5 mg/kg
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Fospropofol 6.5 mg/kg
Number of subjects: 127

Group type: EXPERIMENTAL
Intervention: Fospropofol 8 mg/kg
Number of subjects: 127

Group type: COMPARATOR
Intervention: Midazolam 0.02 mg/kg
Number of subjects: 127
Study: 17189550

Group type: EXPERIMENTAL
Intervention: Antioxidant (AOX) treatment (800 IU of vitamin E, 500 mg of vitamin C, 10 mg of beta-carotene)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Antioxidant (AOX) treatment
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 48
Study: 14586351

Group type: EXPERIMENTAL
Intervention: Grand multiparous women
Number of subjects: 0

Group type: COMPARATOR
Intervention: Lower parity multiparous women
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nulliparous women
Number of subjects: 0
Study: 10756219

Group type: EXPERIMENTAL
Intervention: Zafirlukast
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 8823240

Group type: EXPERIMENTAL
Intervention: Eptastigmine 20 mg
Number of subjects: 103

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study: 29807257

Group type: EXPERIMENTAL
Intervention: Dilute vinegar lavage (20 mL of vinegar in 1 L saline) every second day during each estrus period (n=4)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control group (n=4)
Number of subjects: 8
Study: 27578134

Group type: EXPERIMENTAL
Intervention: Mipomersen treatment
Number of subjects: 64
Study: 25641909

Group type: EXPERIMENTAL
Intervention: RESMENA diet (Mediterranean dietary pattern)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Control diet (American Heart Association guidelines)
Number of subjects: 72
Study: 23013806

Group type: EXPERIMENTAL
Intervention: Structured Training and Assessment Curriculum (STAC)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional residency training
Number of subjects: 20
Study: 21964962

Group type: EXPERIMENTAL
Intervention: Heavy smoking
Number of subjects: 1344

Group type: EXPERIMENTAL
Intervention: Heavy smoking with slow CYP2A6 genotype
Number of subjects: 1344

Group type: EXPERIMENTAL
Intervention: Heavy smoking with poor CYP2A6 genotype
Number of subjects: 1344
Study: 18569272

Group type: EXPERIMENTAL
Intervention: 3% diclofenac gel applied once daily
Number of subjects: 49

Group type: COMPARATOR
Intervention: 5% imiquimod cream applied three times a week for 12 weeks
Number of subjects: 49
Study: 16048853

Group type: EXPERIMENTAL
Intervention: Integrated, multifaceted depression treatment model
Number of subjects: 2

Group type: COMPARATOR
Intervention: Geriatric Care Management Program
Number of subjects: 2
Study: 11831837

Group type: EXPERIMENTAL
Intervention: Simvastatin 40 mg
Number of subjects: 20500

Group type: COMPARATOR
Intervention: Antioxidant vitamin cocktail (650 mg vitamin E, 250 mg vitamin C, 20 mg beta-carotene)
Number of subjects: 20500
Study: 10051255

Group type: EXPERIMENTAL
Intervention: Patient education for asthma (two 2-hour group sessions and one to two individual sessions by a nurse and physiotherapist)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Patient education for asthma
Number of subjects: 140

Group type: COMPARATOR
Intervention: Control group (no patient education)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Patient education for COPD
Number of subjects: 140
Study: 8559480

Group type: EXPERIMENTAL
Intervention: Presence of 50% or more cellular crescents
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Less extensive cellular crescents plus moderate to severe interstitial fibrosis
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Azotaemia, anaemia, hypocomplementaemia, hypertension, tubular atrophy, glomerular sclerosis
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Serum creatinine, haematocrit, race, kidney pathology data
Number of subjects: 166
Study: 1904198

Group type: EXPERIMENTAL
Intervention: 20 mg/kg praziquantel
Number of subjects: 536

Group type: EXPERIMENTAL
Intervention: 40 mg/kg praziquantel
Number of subjects: 536

Group type: COMPARATOR
Intervention: Both dosages of praziquantel
Number of subjects: 536
Study: 7015172

Group type: EXPERIMENTAL
Intervention: Low dose subcutaneous heparin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no heparin)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Heparin group
Number of subjects: 0
Study: 29914300

Group type: EXPERIMENTAL
Intervention: Prism adaptation with concurrent exposure
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Prism adaptation with terminal exposure
Number of subjects: 24
Study: 30374818

Group type: COMPARATOR
Intervention: 41.4 Gy (low-dose)
Number of subjects: 8881

Group type: EXPERIMENTAL
Intervention: 50.4 Gy (high-dose)
Number of subjects: 8881

Group type: EXPERIMENTAL
Intervention: 45 Gy (moderate-dose)
Number of subjects: 8881
Study: 28644907

Group type: EXPERIMENTAL
Intervention: Short-fasting group (fasted until the day after ESD)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Long-fasting group (fasted until 2 days after ESD)
Number of subjects: 101

Group type: EXPERIMENTAL
Intervention: Short-fasting group
Number of subjects: 101

Group type: COMPARATOR
Intervention: Long-fasting group
Number of subjects: 101
Study: 26188541

Group type: EXPERIMENTAL
Intervention: Metformin treatment
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Metformin treatment in type 2 diabetes patients
Number of subjects: 40

Group type: COMPARATOR
Intervention: Matched controls (n = 44)
Number of subjects: 40
Study: 23987302

Group type: EXPERIMENTAL
Intervention: 3-month telephone-based behavioral counseling intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Attention control nutrition education intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cotinine bioverification
Number of subjects: 0
Study: 21488751

Group type: EXPERIMENTAL
Intervention: Atomoxetine (ATX) fast: 7 days at 0.5 mg/kg, then 1.2 mg/kg
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Atomoxetine (ATX) slow: 7 days each at 0.5 and 0.8 mg/kg, then 1.2 mg/kg
Number of subjects: 181

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Atomoxetine (ATX) pooled
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Atomoxetine (ATX) slow
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Atomoxetine (ATX) fast
Number of subjects: 181
Study: 20301983

Group type: EXPERIMENTAL
Intervention: Orlistat (three times a day) plus a reduced calorie diet (600 kcal/day deficit)
Number of subjects: 166

Group type: COMPARATOR
Intervention: Placebo plus a reduced calorie diet (600 kcal/day deficit)
Number of subjects: 166
Study: 17196810

Group type: EXPERIMENTAL
Intervention: DE+O(3) exposure (1-h DE exposure at PM-concentration of 300 microg/m(3) followed by 2-h exposure to 0.2 ppm O(3))
Number of subjects: 0

Group type: COMPARATOR
Intervention: DE+air exposure (1-h DE exposure at PM-concentration of 300 microg/m(3) followed by 2-h exposure to filtered air)
Number of subjects: 0
Study: 15201546

Group type: EXPERIMENTAL
Intervention: Amlodipine 5-10 mg
Number of subjects: 166

Group type: COMPARATOR
Intervention: Lisinopril 10-20 mg
Number of subjects: 166

Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 166

Group type: COMPARATOR
Intervention: Lisinopril
Number of subjects: 166
Study: 11345750

Group type: EXPERIMENTAL
Intervention: Sevoflurane alone (S group)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Propofol and sevoflurane (PS group)
Number of subjects: 30
Study: 9154869

Group type: EXPERIMENTAL
Intervention: Inverse ratio ventilation (IRV) (I/E = 2)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Conventional ventilation (CV) (I/E = 0.5)
Number of subjects: 8
Study: 8431748

Group type: EXPERIMENTAL
Intervention: DuoDERM E (DE)
Number of subjects: 60

Group type: COMPARATOR
Intervention: scarlet red (SR)
Number of subjects: 60
Study: 3116980

Group type: EXPERIMENTAL
Intervention: Norepinephrine (40 ng/kg/min; i.v.)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo (glucose)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Norepinephrine (10 and 20 ng/kg/min; i.v.)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Normotensive subjects (control group)
Number of subjects: 28
Study: 31988225

Group type: EXPERIMENTAL
Intervention: Dynamic LED-light
Number of subjects: 150

Group type: COMPARATOR
Intervention: Static LED-light
Number of subjects: 150
Study: 29845723

Group type: EXPERIMENTAL
Intervention: Imarikiren 5 to 200 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Imarikiren 50 mg (Food Effect part)
Number of subjects: 60
Study: 28126541

Group type: EXPERIMENTAL
Intervention: Levonorgestrel emergency contraceptive (1.5mg)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Ulipristal acetate emergency contraceptive (30mg)
Number of subjects: 32
Study: 27025129

Group type: EXPERIMENTAL
Intervention: Remaxol at a dose of 800 mg/day for 7 days
Number of subjects: 44
Study: 23910198

Group type: EXPERIMENTAL
Intervention: Open surgical technique
Number of subjects: 62

Group type: COMPARATOR
Intervention: Closed surgical technique
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Operated canines (both techniques combined)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Operated canines
Number of subjects: 62
Study: 21529363

Group type: EXPERIMENTAL
Intervention: Exenatide QW (2 mg)
Number of subjects: 295
Study: 18442484

Group type: EXPERIMENTAL
Intervention: Narrow band imaging (NBI)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Standard resolution endoscopy
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Narrow band directed biopsies
Number of subjects: 65

Group type: COMPARATOR
Intervention: Standard resolution endoscopy with random biopsy
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Narrow band targeted biopsies
Number of subjects: 65
Study: 17041074

Group type: EXPERIMENTAL
Intervention: Evidence-based practice (EBP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study: 12207128

Group type: EXPERIMENTAL
Intervention: 0.05 mg/kg piritramide intravenously (group A)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Normal saline intravenously (group B)
Number of subjects: 60
Study: 10491673

Group type: EXPERIMENTAL
Intervention: In-home prenatal nutrition intervention
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 40
Study: 8941514

Group type: EXPERIMENTAL
Intervention: Chronic hypoxia training (HT); barometric pressure = 500 mmHg; inspired O2 fraction = 0.209
Number of subjects: 20

Group type: COMPARATOR
Intervention: Acute normoxia training (NT); barometric pressure = 500 mmHg; inspired O2 fraction = 0.314
Number of subjects: 20
Study: 1849152

Group type: EXPERIMENTAL
Intervention: Antacid (30 mL Maalox) with 500 mg azithromycin
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Cimetidine (800 mg) 2 hours before 500 mg azithromycin
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo before 500 mg azithromycin
Number of subjects: 22
Study: 6639916

Group type: EXPERIMENTAL
Intervention: Fish-oil concentrate (MaxEPA), 10 g daily for 2 weeks
Number of subjects: 10

Group type: COMPARATOR
Intervention: Vegetable oil supplement, 10 g daily for 2 weeks
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Both supplements
Number of subjects: 10
Study: 30237548

Group type: EXPERIMENTAL
Intervention: Collagenase clostridium histolyticum (CCH)
Number of subjects: 45
Study: 30998693

Group type: EXPERIMENTAL
Intervention: Exposure to media concerning facility delivery
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: Antenatal care (ANC) attendance less than 4 times
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: Timing of first ANC visit in the 2nd and 3rd trimesters of pregnancy
Number of subjects: 420
Study: 28272464

Group type: EXPERIMENTAL
Intervention: HF/HC diet
Number of subjects: 29

Group type: COMPARATOR
Intervention: HC/HF diet
Number of subjects: 29
Study: 25388552

Group type: EXPERIMENTAL
Intervention: Patient education combined with exercise therapy (supervised exercises 3 times/week for 3 months)
Number of subjects: 121

Group type: COMPARATOR
Intervention: Patient education alone
Number of subjects: 121

Group type: EXPERIMENTAL
Intervention: Patient education combined with exercise therapy
Number of subjects: 121
Study: 24115345

Group type: EXPERIMENTAL
Intervention: 6-session body image programme
Number of subjects: 448

Group type: COMPARATOR
Intervention: usual curriculum control
Number of subjects: 448
Study: 21683609

Group type: EXPERIMENTAL
Intervention: Radiofrequency sympathicolysis
Number of subjects: 58

Group type: COMPARATOR
Intervention: Surgical sympathectomy
Number of subjects: 58
Study: 19114437

Group type: EXPERIMENTAL
Intervention: Intradialytic exercise training (Group A)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group (Group B)
Number of subjects: 35
Study: 16911633

Group type: EXPERIMENTAL
Intervention: Calcitriol (0.25 microg on alternate days)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Nicotinamide (25 mg/kg daily)
Number of subjects: 70
Study: 15298633

Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg twice daily
Number of subjects: 25

Group type: COMPARATOR
Intervention: Esomeprazole 40 mg once daily
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg twice daily
Number of subjects: 25
Study: 11871864

Group type: EXPERIMENTAL
Intervention: High-dose chemotherapy (HDCT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional-dose chemotherapy
Number of subjects: 0
Study: 9388818

Group type: EXPERIMENTAL
Intervention: 0.1 IU/kg body weight of rhGH
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: 0.2 IU/kg body weight of rhGH
Number of subjects: 69

Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 69
Study: 7716662

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin prophylaxis
Number of subjects: 51

Group type: COMPARATOR
Intervention: No prophylaxis (Control)
Number of subjects: 51
Study: 3330988

Group type: EXPERIMENTAL
Intervention: Nifedipine/diuretic
Number of subjects: 71

Group type: COMPARATOR
Intervention: Placebo/diuretic
Number of subjects: 71
Study: 29464473

Group type: EXPERIMENTAL
Intervention: Baseline sleep screening using Pittsburgh Sleep Quality Index (PSQI) and Epworth Sleepiness Scale (ESS)
Number of subjects: 281
Study: 27608206

Group type: COMPARATOR
Intervention: Fractional microneedling radiofrequency (FMR) treatment on one side of the cheeks, two sessions with a 4-week interval.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Untreated side (control)
Number of subjects: 0
Study: 24372823

Group type: EXPERIMENTAL
Intervention: Fluoride varnish (F)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Chlorhexidine-thymol varnish (CHX/T)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo varnish
Number of subjects: 75
Study: 24002086

Group type: EXPERIMENTAL
Intervention: escitalopram (n=80)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: nortriptyline (n=33)
Number of subjects: 113
Study: 20300033

Group type: COMPARATOR
Intervention: Method A (5 minutes of jogging)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Method C (5 minutes of jogging and dynamic exercise)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Method D (5 minutes of jogging and a combination of static stretching and dynamic exercise)
Number of subjects: 26
Study: 19378580

Group type: EXPERIMENTAL
Intervention: Infragluteal sciatic nerve block (Group 1) with 30 mL of 0.5% bupivacaine (S75/R25) with 1:200,000 epinephrine
Number of subjects: 28

Group type: COMPARATOR
Intervention: Parasacral sciatic nerve block (Group 2) with 30 mL of 0.5% bupivacaine (S75/R25) with 1:200,000 epinephrine
Number of subjects: 28
Study: 16427366

Group type: EXPERIMENTAL
Intervention: Placebo treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 0
Study: 15018685

Group type: EXPERIMENTAL
Intervention: Evaluation by an attractive female observer
Number of subjects: 4

Group type: COMPARATOR
Intervention: Evaluation by an attractive male observer
Number of subjects: 4

Group type: COMPARATOR
Intervention: No evaluation
Number of subjects: 4
Study: 10958101

Group type: EXPERIMENTAL
Intervention: 200 mg tramadol
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 8630631

Group type: EXPERIMENTAL
Intervention: Meloxicam 7.5 mg
Number of subjects: 423

Group type: EXPERIMENTAL
Intervention: Meloxicam 15 mg
Number of subjects: 423

Group type: COMPARATOR
Intervention: Meloxicam 7.5 mg and Meloxicam 15 mg
Number of subjects: 423
Study: 1465080

Group type: EXPERIMENTAL
Intervention: Low protein intake (0.8‐1.1 g/kg/day)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Free protein intake (control group)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Both groups (diet and control)
Number of subjects: 200
Study: 434623

Group type: EXPERIMENTAL
Intervention: Cerium nitrate-silver sulfadiazine
Number of subjects: 34

Group type: COMPARATOR
Intervention: Silver sulfadiazine
Number of subjects: 34
Study: 31235374

Group type: EXPERIMENTAL
Intervention: BBio bOPV
Number of subjects: 1080

Group type: COMPARATOR
Intervention: SII bOPV
Number of subjects: 1080

Group type: EXPERIMENTAL
Intervention: BBio bOPV (3 lots)
Number of subjects: 1080

Group type: EXPERIMENTAL
Intervention: BBio bOPV and SII bOPV
Number of subjects: 1080
Study: 27788625

Group type: EXPERIMENTAL
Intervention: Ridge Preservation (RP) with freeze-dried bone allograft and non-resorbable dense polytetrafluoroethylene membrane
Number of subjects: 40

Group type: COMPARATOR
Intervention: No Ridge Preservation (no RP)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Ridge Preservation (RP)
Number of subjects: 40
Study: 26451096

Group type: EXPERIMENTAL
Intervention: Helium/oxygen mixture (78%/22%)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Medical air
Number of subjects: 30
Study: 23076450

Group type: EXPERIMENTAL
Intervention: Aliskiren/amlodipine combination therapy
Number of subjects: 1688

Group type: COMPARATOR
Intervention: Aliskiren 150 mg
Number of subjects: 1688

Group type: COMPARATOR
Intervention: Aliskiren 300 mg
Number of subjects: 1688

Group type: COMPARATOR
Intervention: Amlodipine 5 mg
Number of subjects: 1688

Group type: COMPARATOR
Intervention: Amlodipine 10 mg
Number of subjects: 1688
Study: 21871978

Group type: EXPERIMENTAL
Intervention: INT reconstruction
Number of subjects: 103

Group type: COMPARATOR
Intervention: RY reconstruction
Number of subjects: 103